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Prolonged extracorporeal membrane oxygenation for children with respiratory failure
Thomas V. Brogan, MD; Luke Zabrocki, MD; Ravi R. Thiagarajan, MBBS, MPH; Peter T. Rycus, MPH; Susan L. Bratton, MD, MPH E xtracorporeal membrane oxygenation (ECMO) has been used successfully to support or "rescue" children with severe acute respiratory failure who fail less invasive support modes (1) (2) (3) (4) (5) (6) . A study from the mid-1990s by Green et al (4) suggested that ECMO conferred a survival benefit in children with acute respiratory failure. Although management of respiratory failure has since changed, large variability between and within institutions remains, thus limiting accurate risk assessment for children treated with conventional ventilator management or ECMO (7) (8) (9) (10) . ECMO carries with it profound risk resulting from the requirement of large-bore catheters, systemic anticoagulation, and the danger of thromboemboli, especially in patients supported on venoarterial ECMO (11) . Outcomes of patients on ECMO may also be affected by the vagaries of the primary illness, underlying comorbidities, superinfection, and mechanical complications (5) . The risk of death and disability increases with ECMO-associated complications, (9) (10) (11) (12) (13) and decreased survival has been reported with increasing duration of the ECMO course (5) .
A recent review of the Extracorporeal Life Support Organization (ELSO) database demonstrated that mortality increased significantly after 2 wks of mechanical ventilation before ECMO, although earlier studies suggested that 1 wk of ventilation increased the risk of death from ventilator-associated lung injury (1, 5) . It remains unclear how such pre-ECMO factors affect the time course of prolonged use of ECMO. Another concern in children with respiratory failure who are supported for many weeks is at what point does the chance of survival become exceedingly small and the risks of continued ECMO support outweigh potential benefits.
A small but clinically significant proportion of children supported with ECMO for respiratory failure have ECMO courses of >21 days. We chose to review retrospectively the ELSO registry for children with courses of ECMO lasting ≥21 days to evaluate this group both for survival and factors associated with mortality, especially to see if a time point existed when ECMO survival dropped to nearly zero.
MATERIALS AND METHODS
ELSO collects case data from over 115 ECMO centers worldwide through voluntary reporting. Data include patient demographics, the primary indication for ECMO support designated as "pulmonary," "cardiac," or "E-CPR" and ECMO support data. The ELSO registry (Ann Arbor, MI) was queried for all pediatric patients ≤18 yrs of age treated for a primary pulmonary indication (n = 3717) from January 1, 1993, to December 31, 2007. Exclusion criteria included ECMO age <30 days (n = 432) and lack of a valid respiratory diagnosis verified by International Classification of Diseases, 9th Revision coding (14) (n = 13). For patients with multiple courses of ECMO, only the index exposure was included. Analyses and reports of the ELSO database including this report are approved by the Registry Committee of ELSO and as analyses of deidentified data by the University of Michigan institutional review board.
Primary diagnosis International Classification of Diseases, 9th Revision codes as well as secondary diagnoses and Current Procedural Terminology codes were examined independently by two investigators (LZ, SB) who assigned a primary respiratory diagnosis. Disagreements (n = 68) were resolved by a third investigator (TB). In a similar fashion, diagnosis codes were also used to determine 11 comorbid conditions. For statistical analysis, ECMO support was classified as venovenous or venoarterial. Children converted to a different mode (venovenous-venoarterial or venoarterial-venovenous) were classified under their final mode. Patients were compared with survival to hospital discharge being the primary outcome measure.
Statistical Analysis. Categorical variables were analyzed using a Fisher's exact test or Pearson chi-square test, whereas continuous variables were analyzed using a Mann-Whitney U test or the Kruskal-Wallis test when comparing more than two groups. All statistical analysis was performed using SPSS 19.0 for Macintosh (Chicago, IL). Significance was determined as p < .05.
Candidate variables for inclusion in a multivariable logistic regression model to evaluate factors associated with mortality before hospital discharge were chosen from those that differed by death in the bivariate analysis. Criteria for variable selection were set at a p value of ≤ .1. A forward selection process was used for entry of variables into the model. Exclusion criteria were p < .05. The variable of pre-extracorporeal cardiopulmonary life support pH was divided into lowest quartile (pH ≤7.22), middle two quartiles (pH 7.221-7.389), and highest quartiles (pH ≥7.39). The variable pre-extracorporeal cardiopulmonary life support peak inspiratory pressure (PIP) was also divided into the lowest quartile (PIP ≤35 cm H 2 O), middle two quartiles (PIP >35 to <54 cm H 2 O), and highest quartile (≥54 cm H 2 O). All data were reported as frequency (n) with proportion (%) or median values with interquartile range (25th-75th percentile) unless otherwise specified.
RESULTS

Patient Demographic, Respiratory Diagnosis, and Comorbid Conditions.
During the study period, 389 (12%) of the 3213 children had an index course of ECMO for respiratory failure that lasted ≥21 days of support (Table 1) . Median patient age in the prolonged support group was 9.1 months (interquartile range, 2.5-41.7 months) and median weight was 6.7 kg (interquartile range, 3.5-15.8 kg). Survival rates for children supported for ≥3 wks was 38%, significantly lower than for patients supported ≤2 wks (61%) and for those receiving 2-3 wks of bypass (53%). Figure 1 shows the rate of survival to discharge for patients remaining on their index course by days on ECMO for all children. By 45 days of support, survival was 27% (n = 22). No patient survived >52 days on ECMO. Table 2 lists the primary diagnoses and comorbidities for children supported with ECMO ≥21 days by hospital survival. No differences were found in survival when analyzed by primary pulmonary diagnoses (p = .10). Only children with aspiration pneumonitis had survival >50%. Patients in the groups "acute respiratory failure, nonacute respiratory distress syndrome," and "other" had the lowest survival.
Pre-ECMO comorbidities did not differ significantly by survival. Twenty-nine percent of patients had at least one comorbidity ( Table 2 ). The most common comorbidities were renal failure (12%) and chronic lung disease (10%). Although the number of children with immune deficiencies was low, their survival exceeded 50%. No patient with single ventricle, myocardial disease, liver failure, or who received a hematopoietic stem cell transplant survived but, again, their numbers were small.
Ventilator Settings and Pre-ECMO Therapies. The median duration of mechanical ventilation before ECMO initiation in both groups was approximately 6 days. Pre-ECMO duration of mechanical ventilation was not associated with hospital survival (Table 3) . Survival was not associated with duration of pre-ECMO ventilation. Mode of ventilator support was not associated with survival in the children who received prolonged ECMO support and likewise survival did not significantly differ when examining ECMO mode. Adjunctive therapies used before the institution of ECMO did not differ between survivors and nonsurvivors (Table 3) .
Pre-ECMO ventilator settings did not differ between survivors and nonsurvivors except for the level of PIP, which was significantly higher in the nonsurvivor group (Table 4) . Furthermore, no differences were noted between survival and death in blood gas data. Patients in both groups demonstrated respiratory acidosis with partial metabolic compensation. Indicators of gas exchange (PaO 2 , oxygenation index, PaO 2 /Fio 2 ) showed poor oxygenation despite high ventilator settings.
Complications. Both groups had high rates of complications while on ECMO, including circuit complications (Table 5) . Seizures but not central nervous system hemorrhage occurred more frequently among nonsurvivors. Nonsurvivors had a significantly higher rate of renal dysfunction but not receipt of renal replacement therapies. Receipt of inotropic infusions, acidosis (pH <7.20), and pulmonary hemorrhage were more common among children who died. Importantly, although the rate of infection among survivors and nonsurvivors did not differ by survival, the rate of infection exceeded 40% in both groups. The total number of complications by group differed significantly between groups when divided into three or less and more than three complications (49% vs. 62%).
Independent Predictors of Mortality.
A multivariable logistic regression model was developed to evaluate patient demographics and pre-ECMO support characteristics independently associated with mortality (Table 6 ). Male gender, receipt of inotropic infusions, and acidosis while on ECMO increased the odds of death.
DISCUSSION
When ECMO support becomes prolonged, the decision to continue often proves difficult because few data exist to help clinicians prognosticate accurately and guide clinical decisionmaking. In this cohort of children with respiratory failure supported with ECMO for a prolonged duration (≥21 days), survival varied inversely with time on ECMO, contradicting the earlier findings published in the mid-1990s in which survival actually increased in the patients with the longest ECMO runs (15) . Furthermore, there appeared to be no ECMO duration at which a distinct survival stepoff occurred but no patient in this cohort survived >52 days on ECMO (n = 9). So although survival falls steadily with increasing ECMO duration, the survival still exceeded 30% after 4 wks of ECMO support and 27% survived after 45 days of support. A few variables were independently associated with increased odds for death and included male gender, receipt of inotropic infusions on ECMO as well as persistent acidosis despite bypass.
Although these data do not provide a roadmap as to which point to abandon ECMO support, they do suggest that a long-term ECMO course can be met with >25% to 30% survival to discharge in all comers. Pre-ECMO patient demographic characteristics did not influence outcome in this cohort except for gender. Previous studies found that age but not gender was associated with mortality (1, 5, 6, 15, 16) . The lack of an association with age may have been related to the relatively small numbers of patients in this study compared with the prior study evaluating outcomes in all patients supported with ECMO for acute respiratory failure (5). Underlying pulmonary diagnosis and comorbidities did not influence mortality, which contrasts with the findings in the entire pediatric respiratory failure ELSO cohort (5) . A small number of patients had cardiac comorbidities. Although these children may have not had simple respiratory failure, their survival rate did not differ significantly compared with other patients in this cohort or in the study of all children placed on ECMO for respiratory failure. In an earlier study, patients with acute respiratory distress syndrome as a result of sepsis, pertussis, and fungal infections had increased odds of death, whereas those with status asthmaticus, aspiration, and respiratory syncytial virus had decreased odds of death (5) . Furthermore, pre-existing comorbidities including liver failure, cancer, renal failure, and prior cardiac arrest were also shown to increase mortality (5). Nearly one-third of all patients had a chronic comorbidity, and although chronic lung disease and renal failure were the most common, the comorbidity subgroups tended to be small in this cohort. Additionally, the rate of comorbidities has been shown to be increasing among children supported with ECMO for respiratory failure (5). Although preexisting comorbidities and pre-ECMO therapies did not influence survival in patients supported with ECMO for >3 wks, they may have played a role in the need for prolonged ECMO and as such would have decreased survival. A curious finding was the higher rate of survivors who received pre-ECMO cardiopulmonary resuscitation compared with nonsurvivors (6% vs. 1%), which was not statistically significant. This finding most likely represents a function of the small numbers of patients in this study but should be followed in future studies.
Just as pre-ECMO patient characteristics did not affect outcome, pre-ECMO therapies also had no independent association with mortality. The pre-ECMO PIP increased odds of death in the univariate analysis but did not remain significant in the multivariable analysis. Still, peak ventilator pressures in this series before extracorporeal cardiopulmonary life support reached concerning levels, exceeding recommended pressures for patients with acute respiratory distress syndrome (17, 18) . The use of such high distending ventilator pressures almost certainly contributes to lung injury. Previous studies showed oxygenation index, which includes mean airway pressure but not PIP, predicted mortality in children with respiratory failure (19, 20) . The median oxygenation index is this study was 47 and three-fourths of these children had an oxygenation index of ≥33. Furthermore, duration of mechanical ventilation before ECMO has been shown to correlate with mortality but we did not find this to be the case. An early study found that mortality increased after 1 wk of mechanical ventilation, whereas more recent data suggest that mortality does not rise significantly until 2 wks of pre-ECMO ventilation (1, 5) . So, the influence of pre-ECMO therapy may wane with time on ECMO, although a previous study suggested that duration of mechanical ventilation may influence duration of ECMO (15) . Neither ventilator type nor ECMO mode influenced outcome among pediatric patients with prolonged support.
In contrast to the pre-ECMO therapies, complications occurring during ECMO support were common and were associated with mortality. Nearly all patients had at least one complication, whereas two such complications, receipt of inotropic infusion and acidosis despite bypass, were independently associated with mortality. These complications suggest ongoing cardiorespiratory derangement despite ECMO support, which may explain their effect on outcome. In the study by Green et al (15) , ECMO complications did not influence either outcome or duration of ECMO and were not reported in the study by Zabrocki et al (5) . Bleeding and mechanical complications have also been shown to increase duration of ECMO support (15) . The high rate of complications in this population despite their limited influence on outcome remains rather concerning especially, because more than three complications was associated with death in the univariate analysis. Although this finding did not remain significant in the multivariate analysis, multiple complications may contribute to longer runs and may increase long-term sequelae.
This study is subject to several limitations with the most prominently being its retrospective nature. Data are collected and entered retrospectively into the ELSO registry. Limitations exist in the data capture of the registry; for instance, ventilator settings do not include either tidal volumes or plateau pressures. Furthermore, the relative timing and duration of certain variables such as complications or duration of high ventilator settings are not recorded. No standardization occurs regarding which children receive ECMO support and the large variability between and within ECMO centers limits risk assessment for children treated conventionally or with ECMO. Also, ELSO does not release data on individual centers so institutional idiosyncrasies could not be evaluated. Additionally, a large percentage of the patients had diagnoses that are rather nonspecific (e.g., the acute respiratory failure, nonacute respiratory distress syndrome, and "other" categories"). Finally, data on quality of survival and residual respiratory function are lacking, which is important because they may differ greatly from patients supported for briefer periods of time, especially given the frequent complications on ECMO.
CONCLUSIONS
Survival declines with prolonged ECMO support but does so gradually. Complications on ECMO were common, but few factors increased the odds of mortality, especially pre-ECMO diagnoses or therapies. Thus, physicians should be cautiously optimistic with prolonged ECMO runs while assiduously attempting to prevent ECMO complication. Inadequate cardiorespiratory status during ECMO as evidenced by acidosis and receipt of inotropic support during ECMO appears to decrease survival odds and may be important when discussing prognosis and the benefits of continued ECMO support.
